J&J ($JNJ), Takeda recall Velcade on particle fears

Johnson & Johnson ($JNJ) has been hit with another recall, but this time J&J wasn't the company overseeing production. The drug in question is Velcade, the blood cancer treatment, marketed outside the U.S. by a J&J unit; it's sold in the U.S. by Millennium, now a unit of Japan's Takeda Pharmaceuticals. Polyester-like particulates were found in vials from two batches of the drug, which was produced for Millennium by a contract manufacturer.

A Takeda spokesman told Bloomberg that the company is fixing a manufacturing problem linked to the particulates. In the meantime, six lots of Velcade were recalled in Europe and Japan because of the particles; another seven lots in the U.S. will be recalled as a "precaution." According to a Millennium spokeswoman, the company received five reports of particulates in the six European and Japanese lots, but no complaints from U.S. customers.

We've seen several particulate-related recalls in recent months: Baxter pulled Hylenex because glass particles were found in some containers. Hospira recalled propofol because of stainless-steel particles. Then there was the "floating matter" recall of several drugs made by India's Claris LifeSciences for customers such as Pfizer. Separately, of course, there were the repeated J&J recalls, mostly in its McNeil Consumer Healthcare division; the company is overhauling a problem plant in Pennsylvania to get many of those meds back onto the market.

- get the U.K. recall notice
- see the Reuters news
- get more from Bloomberg

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.